Business Wire recently reported that 10X Genomics was ordered to pay $23.9 million in damages for willfully infringing three U.S. patents (patent numbers 8304193, 8329407 and 8889083) owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc. Bio-Rad is a leader in healthcare and life sciences research and is listed on the New York Stock Exchange with ticker symbols BIO and BIOb.
The patents infringed by 10X Genomics are related to Bio-Rad’s droplet microfluidics technologies, such as its Droplet Digital PCR Technology. Bio-Rad President and Chief Executive Officer, Norman Schwartz, stated that “Bio-Rad remains committed to growing and protecting its portfolio of patents in the droplet microfluidics space and to delivering differentiated genomics technologies that enable world class research.”
As of June 1, 2026, the Trademarks Opposition Board (TMOB) requires all confidential evidence and documentation in proceedings under sections 11.13, 38, or 45 of the Trademarks Act (the “Act”) to be…
The sneaker company, 1587 Sneakers, is reportedly suing Kansas City Chiefs players, Patrick Mahomes and Travis Kelce, along with their restaurant partners, for trademark infringement.1587 Sneakers…
As reported by Bloomberg Law News, PEI Licensing (“PEI”), the owner of the Penguin apparel brand, has sued Pudgy Penguins NFT (“Pudgy Penguins”) for trademark infringement.Pudgy Penguins started as a…
Nike is reportedly attempting to revive its classic “Total 90” soccer cleat line, but has encountered an unexpected setback. Total90, LLC has reportedly asserted that Nike is infringing its…
As reported by Bloomberg, attempts to register marks covering the phrases “All Rise” and “Here Comes the Judge” were rejected by the U.S. Court of Appeals for the Federal Circuit. In…
The Federal Court of Appeal’s recent decision in Promotion in Motion, Inc. (PIM Brands, Inc.) v. Hershey Chocolate & Confectionery LLC offers fresh guidance on how courts evaluate survey evidence…
